Company intelligence / Profile preview

NaviFUS

Taipei, Taipei City, Taiwannavifus.com ↗

Ownership: Private
Development stage: Commercial

Overview

NaviFUS has demonstrated in a completed Phase II trial in Taiwan that its focused ultrasound system, when combined with Avastin, improved progression-free survival rates in recurrent glioblastoma patients compared to historical controls. The device has also shown significant reduction in seizure frequency and duration among drug-resistant epilepsy patients. Ongoing pivotal trials are underway, with global expansion into Australia and the U.S.[5].

Therapeutic areas: OncologyNeurology
Modalities: DeviceNanoparticle (via microbubble-enhanced ultrasound drug delivery)Small molecule (as delivered agents)Biologic (as delivered agents)
Industry: Therapeutic Medical Devices

Partnerships

Bracco (ultrasound imaging agents)[3]Brainlab (surgical navigation technology)[5]Genovate Biotechnology Co., Ltd.Focused Ultrasound Foundation [4][5]

Beyond the preview

Go deeper on NaviFUS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NaviFUS.

Explore the full profile